Related Experiment Video
Updated: Apr 28, 2026

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
Published on: April 26, 2024
Selegiline-citalopram combination in patients with Parkinson's disease and major depression
Introduction:
We evaluated the efficacy and safety of the selegiline citalopram combination in the treatment of major depression in patients with Parkinson's disease.
Method:
Eight consecutive depressed outpatients who had received previously selegiline monotherapy or (one patient) selegiline-levodopa combination (the dose of selegiline was 5-10 mg/day in each case) for mild to severe Parkinson's disease were treated with 20 mg citalopram/day. The severity of depression was evaluated on the Hamilton Depression Rating Scale before and 8 weeks after citalopram treatment.
Results:
The majority of the patients (six) responded well to citalopram treatment and no adverse events occurred.
Conclusion:
The combination of a low dose of selegiline (5-10 mg daily) and citalopram (20 mg daily) may be an effective and safe method in the treatment of major depression in patients with Parkinson's disease. (Int J Psych Clin Pract 2000; 4:123-125).
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Antidepressant Drugs: Overview
Drugs Affecting Neurotransmitter Release or Uptake
Parkinson Disease ll: Pathophysiology
